Evolus Inc., of Newport Beach, Calif., reported that second-quarter net revenue was $2.3 million and recognized upon delivery of Jeuveau (prabotulinumtoxinA-xvfs) for injection to customers. The gross margin was 71.4% and may fluctuate in the future due to various marketing programs, the company said.